Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
DNLI
DNLI
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DNLI News
Denali Regains Full Rights to DNL593 Therapy
Apr 06 2026
NASDAQ.COM
Denali Continues Clinical Development of DNL593 After Takeda Collaboration Termination
Apr 03 2026
Newsfilter
Takeda Ends Collaboration Agreement with Denali Therapeutics on DNL593
Apr 03 2026
moomoo
Avaí Bio Initiates Master Cell Bank Manufacturing
Apr 01 2026
Newsfilter
Avaí Bio Initiates Master Cell Bank Manufacturing
Apr 01 2026
PRnewswire
Biotech Landscape Update: Regulatory Approvals and Mergers
Mar 27 2026
NASDAQ.COM
Denali Therapeutics Secures FDA Accelerated Approval for Avlayah
Mar 26 2026
Newsfilter
Denali Receives FDA Accelerated Approval for AVLAYAH
Mar 26 2026
NASDAQ.COM
FDA Approves First Treatment for Hunter Syndrome in Nearly 20 Years
Mar 25 2026
Newsfilter
Denali Therapeutics Receives FDA Approval for Avlayah™ (Tividenofusp Alfa-Eknm) to Treat Hunter Syndrome (MPS II)
Mar 25 2026
moomoo
Denali Therapeutics Receives FDA Approval for New Drug
Mar 25 2026
seekingalpha
Avaí Bio Initiates Key Cell Bank Project for Therapy Development
Mar 24 2026
PRnewswire
Avaí Bio Initiates Key Cell Bank Project for Therapy Development
Mar 24 2026
Newsfilter
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
Mar 09 2026
Benzinga
FDA Rejects Multiple Experimental Drug Applications, Raising Investor Concerns
Mar 06 2026
CNBC
FDA Drug Approval Uncertainty Intensifies
Mar 06 2026
Newsfilter
Show More News
